In a similar manner, the aim here was to scale the associated non-endocytic related side effects of Dyn2 inhibition on breast cancer cells viability and migration potential, especially when these cells are stimulated with exogenous AVP. This evidence concerns the gene DNM2 and breast carcinoma.